Desarrollo, Producción e Innovación en la Investigación científica

Permanent URI for this communityhttp://48.217.138.120/handle/20.500.12272/2392

Browse

Author: search.filters.author.Cussa, JorgelinaSubject: search.filters.subject.ketorolac tromethamine

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Nanostructured SBA-15 host applied in ketorolac tromethamine release system
    (Springer Science+Business Media, 2017) Cussa, Jorgelina; Juárez, Juliana María; Gómez Costa, Marcos Bruno; Anunziata, Oscar Alfreco
    The ordered mesoporous silica SBA-15 has been applied in studies of ketorolac tromethamine adsorption andrelease. The SBA 15 materials with hexagonal and regular structure were obtained using a triblock copolymer Pluronic P123 as a template and TEOS as a silica source. Ketorolac tromethamine was adsorbed into SBA 15 silica nanochan- nels using ethanol as solvent. The physicochemical and textural properties of SBA-15 and ketorolac tromethamine/ SBA-15 were characterized by X-ray diffraction, thermo gravimetric analysis, transmission electron microscopy, fourier transform infrared spectroscopy and BET surface studies. Drug release was evaluated by soaking the loaded silica mesoporous material into a solution of HCl (0.1 N) at initial time (0–2 h) and buffer pH 7 at high times at 37 °C under continuous stirring. Oral commercial Keto tablets (Dolten® ) and Keto solution (Keto power) were study for the contrast. Release studies were performed in order to evaluate the required therapeutic efficacy. SBA 15 provides significant improvement in the controlled release of ketor- olac tromethamine.
  • Thumbnail Image
    Item
    LP-SBA-15/ketorolac nanocomposite: development, characterization, and mathematical modeling of controlled keto release
    (2022) Cussa, Jorgelina; Juárez, Juliana María; Gómez Costa, Marcos Bruno; Anunziata, Oscar Alfredo
    Drug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the nanomaterial LP-SBA-15 as an attractive new host for drug delivery systems due to its high biocompatibility, in vivo biodegradability, and low toxicity. LP-SBA-15/Ketorolac was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and texture analysis, determining the adsorption capacity and its release and achieving the required therapeutic efficacy. The host shows the ordered mesoporous nanochannels with a diameter of 11-12 nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release from the LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental data, the Ritger-Peppas model followed by the Weibull model the best ones. The promising results we obtained for the release of the drug thoroughly using the new material, reaching a rapid initial release rate, and maintaining a constant rate afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range, applying it largely to the treatment of diseases that require a rapid response.
  • Thumbnail Image
    Item
    Síntesis, caracterización y aplicación del nanomaterial lp-sba-15 en la liberación controlada de ketorolac trometamina
    (2020) Juárez, Juliana M.; Gómez Costa, Marcos B.; Cussa, Jorgelina
    Los sistemas controlados de administración de fármacos pueden mantener la concentración de medicamentos en los sitios exactos del cuerpo dentro del rango óptimo y por debajo del umbral de toxicidad, mejorando la eficacia terapéutica y reduciendo la toxicidad. El material LP-SBA-15 es un nuevo huésped prometedor para los sistemas de administración de fármacos debido a su alta biocompatibilidad, biodegradabilidad in vivo y baja toxicidad. Se sintetizó el composite ketorolac-trometamina/LP-SBA-15. La síntesis del material y la carga de ketorolac-trometamina en los poros LP-SBA-15 fue exitosa, como lo demuestran los análisis XRD, FTIR, TGA, TEM y análisis morfologicos. Obtuvimos resultados prometedores para la liberación controlada de fármacos utilizando el nuevo material. La aplicación de estos materiales en la liberación de KETO es innovadora, logrando una alta tasa de liberación inicial y luego manteniendo una liberación más lenta. Esto permite mantener la concentración del fármaco dentro del rango de eficacia terapéutica, siendo altamente aplicable para el tratamiento de enfermedades que necesitan una respuesta rápida.